Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target
Context Therapeutics, Inc.
Context Therapeutics, Inc. CNTX | 0.00 |
Guggenheim analyst Paul Jeng reiterates Context Therapeutics (NASDAQ:
CNTX) with a Buy and maintains $5 price target.
